PDT has a vision of bringing CGM to all who rely on insulin. The first step was to combine insulin delivery and sugar measurement into a single through-the-skin tube that is our core technology. Our device has passed biocompatibility testing and has been studied in humans. Focus is shifting to building a commercial-ready design and a pilot production plant.